• We are a fully integrated vaccine company with two travel vaccines on the market.

  • Dedicated to innovation in vaccine research and development.

  • Valneva’s R&D focuses on vaccines addressing high unmet medical needs.

  • Valneva covers the full value chain from research to market.

Welcome to Valneva
A biotech company developing and commercializing vaccines for infectious diseases with major unmet needs

2017_ABR_Teaser

Download 2017 Valneva Annual Business Report


February 21, 2019
Valneva Reports Strong 2018 Results, Expects Further Growth and Major Pipeline Progression in 2019

Read more

— Stock information

@valnevase




-
— January 31, 2019
Valneva Reports Positive Initial Booster Data and Final Phase 1 Data for its Lyme Disease Vaccine Candidate

Read more
— Vienna Stock Exchange Delisting /
Delisting von der Wiener Börse

Shareholder information
Informationen für Aktionäre


— Financial Calendar
February 21, 2019
2018 Consolidated Financial Statements (unaudited)

A recording of the conference can be accessed here:
Webcast Link


See all dates

AKTUELLES

News in German


 
VALNEVA
LIBRARY


Images, presentations and videos

JAPANESE
ENCEPHALITIS
AND
CHOLERA



learn more
play video Company Video

– Upcoming conferences



March 25-27, 2019
BIO-Europe Spring, Vienna, Austria

April 15-17, 2019

World Vaccine Congress, Washington D.C., US
 
Please update your browser...